Adrenal News

In patients with adrenal insufficiency, salivary cortisol rhythm may serve as a useful biomarker to evaluate the adequacy of glucocorticoid replacement, according to findings from a proof-of-concept study reported in Clinical Endocrinology.

Patients with secondary osteoporosis are 10 times more likely to have primary aldosteronism than patients without osteoporosis, according to findings from an Italian study.

Adolescents and adults with congenital adrenal hyperplasia demonstrated normal psychometric intelligence but had impaired executive functions compared with controls, according to researchers in Sweden.

Most children aged 6 years and younger with classic congenital adrenal hyperplasia experience at least one episode of hypercalcemia, increasing their risk for developing hypercalciuria, nephrocalcinosis and hypertension, according to a retrospective analysis of medical records.

Results of a retrospective review conducted in southern India demonstrate that ectopic Cushing’s syndrome occurred most commonly in association with thoracic tumors.

Participant enrollment has concluded for a phase 3 trial investigating the safety and efficacy of levoketoconazole, a cortisol synthesis inhibitor, for the treatment of endogenous Cushing’s syndrome, according to a press release from Strongbridge Biopharma, the drug’s developer.

Patients with nonfunctioning pituitary adenoma who receive daily hydrocortisone replacement doses greater than 20 mg are at increased risk for death from any cause vs. similar patients receiving lower doses and those without secondary adrenal insufficiency, according to findings published in the European Journal of Endocrinology.

Adults with pheochromocytoma had lower bone mass at the lumbar spine compared with adults with nonfunctional adrenal incidentaloma, according to recent study findings.

Younger patients and women with unilateral primary aldosteronism are more likely to experience a favorable outcome after total adrenalectomy than men or older patients with the condition, according to a retrospective analysis from an international consensus group.

Men with nonmetastatic prostate cancer who received androgen deprivation therapy for 2 years saw no change in leukocyte telomere length when compared with controls who received radiotherapy, according to findings from a case-control study in Australia.